Abstract
Purpose: :
In ischemic retinal diseases, choroid may have a role in the pathophysiology. We evaluated the choroidal thickness in patients with central retinal vein occlusion (CRVO).
Methods: :
We measured the bilateral subfoveal choroidal thickness in 27 patients (mean age 65.0±13.0 years, 18 females and 9 males) with unilateral CRVO using enhanced depth imaging spectral-domain optical coherence tomography. Twenty patients were treated with intravitreal bevacizumab (IVB) and measured the subfoveal choroidal thicknesses before and after treatment.
Results: :
The mean subfoveal choroidal thickness measured in 27 eligible eyes of the 27 patients was 226±84μm, which was significantly thicker than the mean subfoveal choroidal thickness in fellow eyes (207±75μm) (P=0.02, paired t-test). There was strong correlation between CRVO eyes and fellow eyes (r=0.82). The mean central macular thickness of CRVO was 442±80μm. There was no correlation between central macular thickness and subfoveal choroidal thickness. The mean subfoveal choroidal thickness after IVB was 218±72μm, which was significantly thinner than the mean subfoveal choroidal thickness before IVB (228±85μm) (P=0.007, paired t-test).
Conclusions: :
The subfoveal choroidal thickness of CRVO was significantly thicker than fellow eyes. The subfoveal choroidal thickness of CRVO significantly decreased after IVB. Vascular endothelial growth factor in retina may have effects on choroidal thickness.
Keywords: imaging/image analysis: clinical • choroid